Q1 2026 earnings call: revenue +6%, EPS +11%, margin gains and raised 2026 guidance amid policy risks (PAMA/ACA).

Labcorp CEO Adam Schechter gives Barron’s a rundown of the diagnostic giant’s technology-first transformation.

By Sahil Pandey April 30 (Reuters) - Labcorp raised its full-year profit and revenue forecast on Thursday after posting ...

With me today are Adam Schechter, our Chairman and Chief Executive Officer; and Julia Wang, our Executive Vice President and ...

North Carolina-based LabCorp Diagnostics, one of the largest clinical laboratories in the U.S., was forced to shut down its network on Sunday after officials detected suspicious activity, according to ...

Full-year 2026 guidance was raised, assuming enterprise revenue growth of 5% to 6.1% and adjusted EPS between $17.70 and ...

April 30 (Reuters) - Labcorp raised its full-year profit and revenue forecast on Thursday after posting quarterly results ...

Labcorp's revenue grew to $3.54 billion in Q1 2026 as the company's strategy of acquiring outreach laboratory businesses from ...

Labcorp is raising its 2026 guidance, buoyed by demand across its diagnostics and central laboratory businesses. | Labcorp is ...

A large regional health system has saved more than $5 million a year on labor and supplies—and even more with capital expense avoidance—by partnering with Labcorp. Within a period of one year, Labcorp ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The move comes at a time when ...

The Baltimore company showed the path for a company spun out of Johns Hopkins research to grow from a base in the city. Now it will join a prominent, global name in life sciences. Personal Genome ...